Compare · MRK vs RZLT
MRK vs RZLT
Side-by-side comparison of Merck & Company Inc. (MRK) and Rezolute Inc. (RZLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and RZLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $277.18B, about 877.7x RZLT ($315.8M).
- Over the past year, MRK is up 35.3% and RZLT is down 20.3% - MRK leads by 55.7 points.
- MRK has been more active in the news (20 items in the past 4 weeks vs 2 for RZLT).
- MRK has more recent analyst coverage (25 ratings vs 14 for RZLT).
- Company
- Merck & Company Inc.
- Rezolute Inc.
- Price
- $112.17+2.74%
- $3.29+2.81%
- Market cap
- $277.18B
- $315.8M
- 1M return
- -7.19%
- +5.11%
- 1Y return
- +35.33%
- -20.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 20
- 2
- Recent ratings
- 25
- 14
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Rezolute Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Latest MRK
- EVP, Access, Policy & Comms Guindo Chirfi exercised 1,967 shares at a strike of $110.03 and covered exercise/tax liability with 969 shares, increasing direct ownership by 2% to 61,613 units (SEC Form 4)
- Exe V-P & Pres. MMD Chattopadhyay Sanat exercised 2,597 shares at a strike of $110.03 and covered exercise/tax liability with 1,130 shares, increasing direct ownership by 11% to 15,347 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 2,518 shares at a strike of $110.03 and covered exercise/tax liability with 1,241 shares, increasing direct ownership by 0.80% to 161,537 units (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 1,377 shares at a strike of $110.03 and covered exercise/tax liability with 679 shares, increasing direct ownership by 2% to 31,716 units (SEC Form 4)
- SVP Fin. - Global Controller Smart Dalton E. Iii exercised 1,408 shares at a strike of $110.33 and covered exercise/tax liability with 483 shares, increasing direct ownership by 11% to 9,137 units (SEC Form 4)
- Executive VP & President, MRL Li Dean Y covered exercise/tax liability with 2,326 shares and exercised 4,722 shares at a strike of $110.03, increasing direct ownership by 3% to 94,431 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 2,951 shares at a strike of $110.03 and covered exercise/tax liability with 1,454 shares, increasing direct ownership by 2% to 70,897 units (SEC Form 4)
- EVP, Chief HR Officer Larson Betty D exercised 13,435 shares at a strike of $110.81 and covered exercise/tax liability with 5,858 shares, increasing direct ownership by 122% to 13,774 units (SEC Form 4)
- EVP & CFO Litchfield Caroline exercised 3,935 shares at a strike of $110.03 and covered exercise/tax liability with 1,938 shares, increasing direct ownership by 2% to 92,301 units (SEC Form 4)
- Chairman, CEO & President Davis Robert M exercised 13,300 shares at a strike of $110.03 and covered exercise/tax liability with 6,551 shares, increasing direct ownership by 2% to 450,351 units (SEC Form 4)
Latest RZLT
- Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
- Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
- SEC Form 4 filed by Evans Daron
- Amendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.
- Rezolute upgraded by Wedbush with a new price target
- Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
- Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)
- CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)
- CEO Elam Nevan C covered exercise/tax liability with 27,618 shares, decreasing direct ownership by 4% to 613,501 units (SEC Form 4)